TABLE 3.
Clinical trials testing CD39 inhibitors and CD73 inhibitors in cancer therapy
| ClinicalTrials.gov Identifier | Intervention/treatment | Condition or disease | Phase |
|---|---|---|---|
| NCT04262375 |
Durvalumab (PD‐L1 inhibitor) Oleclumab (CD73 inhibitor) |
Non‐small Cell Lung Cancer Renal Cell Carcinoma |
II |
| NCT03773666 |
Durvalumab (PD‐L1 inhibitor) Oleclumab (CD73 inhibitor) |
Muscle Invasive Bladder Cancer | I |
| NCT03616886 |
Paclitaxel Carboplatin MEDI4736 (PD‐L1 inhibitor) MEDI9447 (CD73 inhibitor) |
Triple Negative Breast Cancer | I/II |
| NCT03822351 |
Durvalumab (PD‐L1 inhibitor) Oleclumab (CD73 inhibitor) Monalizumab (NKG2A inhibitor) |
Stage III Non‐small Cell Lung Cancer Unresectable |
II |
| NCT03884556 |
TTX‐030 (CD39 inhibitor) Pembrolizumab (PD‐1 inhibitor) Docetaxel Gemcitabine Nab‐paclitaxel |
Solid Tumor Lymphoma |
I |
| NCT03381274 |
MEDI9447 (CD73 inhibitor) Osimertinib (EGFR inhibitor) AZD4635 (A2AR inhibitor) |
Non‐small Cell Lung Cancer | I/II |
| NCT04089553 |
AZD4635 (A2AR inhibitor) Oleclumab (CD73 inhibitor) Durvalumab (PD‐L1 inhibitor) |
Prostate Cancer Metastatic Castration‐Resistant Prostate Cancer |
II |
| NCT04261075 |
IPH5201 (CD39 inhibitor) Durvalumab (PD‐L1 inhibitor) Oleclumab (CD73 inhibitor) |
Advanced Solid Tumors | I |
Abbreviations: A2AR: A2a receptor; EGFR: epidermal growth factor receptor; NKG2A: NK group 2 member A; PD‐1: programmed death 1; PD‐L1: programmed cell death‐ligand 1.